94 related articles for article (PubMed ID: 32771615)
1. Impact of non-adherence to radiotherapy on 1-year survival in cancer patients in Catalonia, Spain.
Borras JM; Font R; Solà J; Macia M; Tuset V; Arenas M; Eraso A; Verges R; Farré N; Pedro A; Mollà M; Algara M; Solé JM; Mira M; Espinàs JA
Radiother Oncol; 2020 Oct; 151():200-205. PubMed ID: 32771615
[TBL] [Abstract][Full Text] [Related]
2. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain.
Font R; Espinas JA; Barnadas A; Izquierdo A; Galceran J; Saladie F; Marcos-Gragera R; Torrent A; Manchon-Walsh P; Borras JM
Breast Cancer Res Treat; 2019 Jun; 175(3):733-740. PubMed ID: 30887164
[TBL] [Abstract][Full Text] [Related]
3. Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients.
Wollschläger D; Meng X; Wöckel A; Janni W; Kreienberg R; Blettner M; Schwentner L
Breast J; 2018 Mar; 24(2):120-127. PubMed ID: 28685896
[TBL] [Abstract][Full Text] [Related]
4. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
5. A population perspective on the use of external beam radiotherapy in Catalonia, Spain.
Corral J; Solà J; Galceran J; Marcos-Gragera R; Carulla M; Izquierdo Á; Vilardell L; Llauradó L; Espinàs JA; Borras JM
Clin Transl Oncol; 2020 Dec; 22(12):2222-2229. PubMed ID: 32424700
[TBL] [Abstract][Full Text] [Related]
6. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
7. Smoking effect on secondary bladder cancer after external beam radiotherapy for prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Inokuchi J; Tatsugami K; Ohga S; Sasaki T; Nakamura K; Honda H; Eto M
Jpn J Clin Oncol; 2016 Oct; 46(10):952-957. PubMed ID: 27432454
[TBL] [Abstract][Full Text] [Related]
8. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
10. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
12. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
[TBL] [Abstract][Full Text] [Related]
13. Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites.
Porta M; Gallén M; Malats N; Planas J
J Epidemiol Community Health; 1991 Sep; 45(3):225-30. PubMed ID: 1757766
[TBL] [Abstract][Full Text] [Related]
14. Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation.
Feldman AS; Meyer CP; Sanchez A; Krasnova A; Reznor G; Menon M; Kibel AS; Choueiri TK; Lipsitz SR; Sun M; Trinh QD
J Urol; 2017 Nov; 198(5):1061-1068. PubMed ID: 28552709
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
16. The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment.
Liberman D; Jarosek S; Virnig BA; Chu H; Elliott SP
J Urol; 2016 May; 195(5):1459-1463. PubMed ID: 26682759
[TBL] [Abstract][Full Text] [Related]
17. A population-based study of the use and outcome of radical radiotherapy for invasive bladder cancer.
Hayter CR; Paszat LF; Groome PA; Schulze K; Math M; Mackillop WJ
Int J Radiat Oncol Biol Phys; 1999 Dec; 45(5):1239-45. PubMed ID: 10613319
[TBL] [Abstract][Full Text] [Related]
18. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
19. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.
Chaturvedi AK; Engels EA; Gilbert ES; Chen BE; Storm H; Lynch CF; Hall P; Langmark F; Pukkala E; Kaijser M; Andersson M; Fosså SD; Joensuu H; Boice JD; Kleinerman RA; Travis LB
J Natl Cancer Inst; 2007 Nov; 99(21):1634-43. PubMed ID: 17971527
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
